APA (7th ed.) Citation

L, Q., RA, L., HP, H., PA, V. D., E, W., X, L., . . . RAC, H. (2023). An innovative phase 2 proof-of-concept trial design to evaluate SAR445088, a monoclonal antibody targeting complement C1s in chronic inflammatory demyelinating polyneuropathy. Journal of the peripheral nervous system : JPNS, 28(2), 276. https://doi.org/10.1111/jns.12551

Chicago Style (17th ed.) Citation

L, Querol, Lewis RA, Hartung HP, Van Doorn PA, Wallstroem E, Luo X, Alonso-Alonso M, Atassi N, and Hughes RAC. "An Innovative Phase 2 Proof-of-concept Trial Design to Evaluate SAR445088, a Monoclonal Antibody Targeting Complement C1s in Chronic Inflammatory Demyelinating Polyneuropathy." Journal of the Peripheral Nervous System : JPNS 28, no. 2 (2023): 276. https://doi.org/10.1111/jns.12551.

MLA (9th ed.) Citation

L, Querol, et al. "An Innovative Phase 2 Proof-of-concept Trial Design to Evaluate SAR445088, a Monoclonal Antibody Targeting Complement C1s in Chronic Inflammatory Demyelinating Polyneuropathy." Journal of the Peripheral Nervous System : JPNS, vol. 28, no. 2, 2023, p. 276, https://doi.org/10.1111/jns.12551.